By 2030, 70 percent of HIV patients will be over 50. Now success of HIV drugs poses a new challenge: treating it as a geriatric condition.
Breaking down a bullish bet on Gilead in the options market with "Fast Money" trader Dan Nathan.
Discussing the potential downside to pharmaceutical companies developing cures with Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy, and Brian Skorney, Baird biotechnology analyst. CNBC's Meg Tirrell also weighs in.
CNBC's Meg Tirrell reports on Gilead's new drug that cures Hepatitis C.
The "Fast Money" traders discuss the trade on Gilead, which is down about 9 percent.
Gilead said it predicts 2017 hepatitis C drug sales of $7.5 billion to $9 billion, lower than the $12 billion Wall Street had expected.
CNBC PRO screened for analysts' favorite Nasdaq 100 stocks to ride out the potential next leg of the rally.
Shares of Gilead Sciences are in the red after the drugmaker issued a weak sales forecast for its hepatitis C drugs.
Some of the names on the move ahead of the open.
CNBC's Meg Tirrell takes a closer look at drugs with the biggest exposure to Medicare spending, as President Trump leans towards Medicare negotiation. The "Fast Money" traders weigh in.
U.S. equities closed mixed as energy capped gains, while investors focused on a slew of corporate earnings reports.
Earnings are out for Gilead. CNBC's Meg Tirrell reports the details.
U.S. stock index futures pointed to a higher open on Tuesday as traders eyed a big day of earnings and economic data.
Disney, General Motors and BP are on the list of companies reporting earnings Tuesday, as traders look for more clarity on Trump's agenda.
There are buying opportunities in biotech and drug stocks despite the backlash from the repeal of Obamacare.
Andrew Keene, CEO at AlphaShark.com, weighs in on the impact Donald Trump's meeting with pharmaceutical company heads.
Tom Lee, Fundstrat Global Advisors, discusses what is left to buy in the markets at Dow 20K, including C.R.A.P., his acronym for Computers, Resources, American Banks and Phone Carriers. The "Fast Money" traders weigh in.
Many blue-chips in various sectors — from biotech to energy — are still trading at low valuations and offer value for investors.
Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy & Outcomes director, discusses why the government should "nationalize" Gilead to help reduce the price of hepatitis C drugs.
Jim Cramer quickly provided his opinion on various stocks from callers in the lightning round.